Table 3.
Overall incidence of major events after the index stroke or TIA
| Index stroke (N = 327) | Index TIA (N = 270) | p-valuea | |||||
|---|---|---|---|---|---|---|---|
| Events, n (%) | Patient-years | Incidence rate % pt-yrs (95% CI) | Events, n (%) | Patient-years | Incidence rate % pt-yrs (95% CI) | ||
| Thrombotic events, n = 113 | 54 (17) | 1179 | 4.41 (3.36–5.79) | 59 (22) | 1168 | 4.97 (3.84–6.42) | 0.5350 |
| Arterial thrombosis, n = 86 | 38 (12) | 1228 | 3.10 (2.25–4.25) | 48 (18) | 1199 | 3.92 (2.94–5.22) | 0.2814 |
| Unstable angina pectoris | 1 (0.3) | 1 (0.4) | |||||
| Acute myocardial infarction | 4 (1.2) | 1308 | 0.31 (0.11–0.82) | 10 (3.7) | 1350 | 0.67 (0.35–1.28) | 0.1982 |
| TIA+ | 13 (4.0) | 1290 | 1.01 (0.59–1.74) | 29 (10.7) | 1243 | 2.33 (1.62–3.36) | 0.0098 |
| Stroke+ | 15 (4.6) | 1291 | 1.6 (0.70–1.93) | 4 (1.5) | 1378 | 0.29 (0.11–0.77) | 0.0079 |
| Peripheral artery thrombosis | 4 (1.2) | 4 (1.5) | |||||
| Splenic infarction | 1 (0.3) | 0 (0) | |||||
| +TIA + stroke, n = 61 | 28 (9) | 1255 | 2.23 (1.54–3.23) | 33 (12) | 1240 | 2.66 (1.89–3.74) | 0.4959 |
| Venous thrombosis, n = 27 | 16 (5) | 1278 | 1.10 (0.65–1.85) | 11 (4) | 1349 | 0.82 (0.45–1.47) | 0.4709 |
| DVT of the legs | 5 (1.5) | 7 (2.6) | |||||
| DVT of the legs + PE | 3 (0.9) | 2 (0.7) | |||||
| Pulmonary embolism | 2 (0.6) | 0 (0) | |||||
| Superficial vein thrombosis | 2 (0.6) | 1 (0.4) | |||||
| Hepatic vein thrombosis | 1 (0.3) | 0 (0) | |||||
| Splanchnic vein thrombosis | 2 (0.6) | 0 (0) | |||||
| Cerebral vein thrombosis | 1 (0.3) | 0 (0) | |||||
| Retinal vein thrombosis | 0 (0) | 1 (0.4) | |||||
| Major bleeding, n = 25 | 15 (5) | 1299 | 1.08 (0.64–1.82) | 10 (4) | 1355 | 0.74 (0.40–1.37) | 0.3681 |
| Intracranial bleeding | 6 (1.8) | 2 (0.7) | |||||
| Gastrointestinal bleeding | 3 (0.9) | 5 (1.9) | |||||
| Other sites | 6 (1.8) | 3 (1.1) | |||||
| Evolution to MF, n = 19 | 9 (3) | 1308 | 0.69 (0.36–1.32) | 10 (4) | 1356 | 0.66 (0.35–1.28) | 0.9407 |
| Evolution to AML, n = 17 | 6 (2) | 1326 | 0.45 (0.20–1.01) | 11 (4) | 1380 | 0.80 (0.44–1.44) | 0.2713 |
| Second neoplasia, n = 51 | 26 (8) | 1273 | 2.04 (1.39–3.00) | 25 (9) | 1341 | 1.79 (1.20–2.67) | 0.6435 |
| Breast | 5 (1.5) | 5 (1.9) | |||||
| Gastrointestinal/liver | 3 (0.9) | 5 (1.9) | |||||
| Kidney | 0 (0) | 2 (0.7) | |||||
| Lung | 1 (0.3) | 1 (0.4) | |||||
| Lymphoma/CLL | 3 (0.9) | 2 (0.7) | |||||
| Prostate/bladder | 5 (1.5) | 2 (0.4) | |||||
| Skin | 4 (1.2) | 4 (1.5) | |||||
| Other | 5 (1.5) | 4 (1.5) | |||||
| Death, n = 102 | 61 (19) | 1327 | 4.37 (3.38–5.66) | 41 (15) | 1381 | 2.97 (2.19–4.03) | 0.0572 |
| Cardiovascular | 26 (8.0) | 1327 | 1.73 (1.15–2.61) | 8 (3.0) | 1381 | 0.58 (0.29–1.16) | 0.0050 |
| Infection | 4 (1.2) | 4 (1.5) | |||||
| MF | 1 (0.3) | 1 (0.4) | |||||
| AML | 6 (1.8) | 8 (3.0) | |||||
| Second neoplasia | 4 (1.2) | 7 (2.6) | |||||
| Hemorrhage | 0 (0) | 1 (0.4) | |||||
| Unknown | 20 (18.7) | 12 (4.4) | |||||
aTests for differences in incidence rates